© 2020 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Deepak L. Bhatt, MD, MPH
John W. Eikelboom, MBBS
Stuart J. Connolly, MD
P. Gabriel Steg, MD
Sonia S. Anand, MD
Subodh Verma, MD, PhD
Kelley R.H. Branch, MD
Jeffrey Probstfield, MD
Jackie Bosch, PhD
Olga Shestakovska, MSc
Michael Szarek, PhD
Aldo Pietro Maggioni, MD
Petr Widimsky, MD
Alvaro Avezum, MD
Rafael Diaz, MD
Basil S. Lewis, MD
Scott D. Berkowitz, MD
Keith A.A. Fox, MBChB
Lars Ryden, MD
Salim Yusuf, DPhil
On behalf of the COMPASS Steering Committee and Investigators*

* A complete list of COMPASS Steering Committee and Investigators is provided in the Appendix.

**Key Words:** anticoagulants ➤ coronary artery disease ➤ diabetes mellitus ➤ peripheral artery disease ➤ platelet aggregation inhibitors

**Sources of Funding,** see page 1852

© 2020 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

https://www.ahajournals.org/journal/circ

**REGISTRATION:** URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424.

**BACKGROUND:** Patients with established coronary artery disease or peripheral artery disease often have diabetes mellitus. These patients are at high risk of future vascular events.

**METHODS:** In a prespecified analysis of the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies), we compared the effects of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily) versus placebo plus aspirin in patients with diabetes mellitus versus without diabetes mellitus in preventing major vascular events. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included all-cause mortality and all major vascular events (cardiovascular death, myocardial infarction, stroke, or major adverse limb events, including amputation). The primary safety end point was a modification of the International Society on Thrombosis and Haemostasis criteria for major bleeding.

**RESULTS:** There were 10 341 patients with diabetes mellitus and 17 054 without diabetes mellitus in the overall trial. A consistent and similar relative risk reduction was seen for benefit of rivaroxaban plus aspirin (n=9152) versus placebo plus aspirin (n=9126) in patients both with (n=6922) and without (n=11 356) diabetes mellitus for the primary efficacy end point (hazard ratio, 0.74, P=0.002; and hazard ratio, 0.77, P=0.005, respectively, \( P_{\text{interaction}}=0.77 \)) and all-cause mortality (hazard ratio, 0.81, \( P=0.05 \); and hazard ratio, 0.84, \( P=0.09 \), respectively; \( P_{\text{interaction}}=0.82 \)). However, although the absolute risk reductions appeared numerically larger in patients with versus without diabetes mellitus, both subgroups derived similar benefit (2.3% versus 1.4% for the primary efficacy end point at 3 years, Gail-Simon qualitative \( P_{\text{interaction}}<0.0001 \); 1.9% versus 0.6% for all-cause mortality, \( P_{\text{interaction}}=0.02 \); 2.7% versus 1.7% for major vascular events, \( P_{\text{interaction}}<0.0001 \)). Because the bleeding hazards were similar among patients with and without diabetes mellitus, the prespecified net benefit for rivaroxaban appeared particularly favorable in the patients with diabetes mellitus (2.7% versus 1.0%; Gail-Simon qualitative \( P_{\text{interaction}}=0.001 \)).

**CONCLUSIONS:** In stable atherosclerosis, the combination of aspirin plus rivaroxaban 2.5 mg twice daily provided a similar relative degree of benefit on coronary, cerebrovascular, and peripheral end points in patients with and without diabetes mellitus. Given their higher baseline risk, the absolute benefits appeared larger in those with diabetes mellitus, including a 3-fold greater reduction in all-cause mortality.

**REGISTRATION:** URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424.
D iabetes mellitus is a commonly occurring major risk amplifier in patients with established atherosclerosis.\textsuperscript{1–4} In particular, those with polyvascular disease, a marker of significant clinical atherosclerotic burden, and concomitant diabetes mellitus, which frequently coexist, constitute a very high-risk group of patients subject to coronary, cerebral, and peripheral ischemic events.\textsuperscript{1,5,6} Lipid-lowering therapies and glycemia-modifying drugs can help attenuate this risk.\textsuperscript{7–18}

Despite effective control of other risk factors, diabetes mellitus still contributes to a prothrombotic state and residual cardiovascular risk.\textsuperscript{19} Antiplatelet therapy, including dual antiplatelet therapy, has been established as effective across a wide variety of stable atherosclerotic patients, with some suggestion of heightened benefit in those with diabetes mellitus at baseline.\textsuperscript{20–29}

More recently, a strategy of dual pathway antithrombotic therapy with an antiplatelet and a reduced-dose anticoagulant has been tested and shown to be effective.\textsuperscript{30–38} The COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) demonstrated that aspirin plus rivaroxaban 2.5 mg twice daily was superior to aspirin plus rivaroxaban placebo for the reduction of ischemic events in 27,395 patients with coronary artery disease or peripheral artery disease. A significant reduction in cardiovascular death was seen with dual pathway inhibition, as well as lower all-cause mortality.

In the present prespecified analysis of COMPASS, we analyzed the results of rivaroxaban plus aspirin versus aspirin alone in the subgroups of patients with or without diabetes mellitus at baseline.

**METHODS**

The data that support the findings of this study may be made available from the corresponding author on reasonable request. The design and results of the overall COMPASS trial have been previously published. In brief, COMPASS was a multicenter, double-blind, randomized, placebo-controlled trial of 27,395 patients with a history of coronary artery disease or peripheral artery disease. Patients were randomized to aspirin plus rivaroxaban placebo, rivaroxaban (5 mg twice daily) plus aspirin placebo, or double antithrombotic therapy with aspirin plus rivaroxaban 2.5 mg twice daily. The primary outcome was cardiovascular death, myocardial infarction (MI), or stroke. Secondary end points included all-cause mortality and major adverse limb events. We also analyzed all major ischemic vascular events (cardiovascular death, MI, stroke, and major adverse limb events, including amputation). The primary safety end point was a modification of the International Society on Thrombosis and Haemostasis criteria for major bleeding. The prespecified net clinical benefit was defined as MI, stroke, cardiovascular death, or bleeding leading to death or symptomatic bleeding into a critical organ. The protocol was approved by the relevant health authorities and institutional review boards. Written informed consent was required from all participants.

The trial was stopped early at the recommendation of the independent data and safety monitoring board because of the overwhelming efficacy of the rivaroxaban plus aspirin arm versus aspirin alone. This analysis focuses on the 18,278 patients in those 2 study groups and compares the outcomes in those with and those without diabetes mellitus according to the case history at baseline.

**Statistical Analysis**

Analyses were conducted according to the intention-to-treat principle. We compared baseline characteristics of patients with and without diabetes mellitus at baseline using Wilcoxon 2-sample tests for continuous variables and Pearson $\chi^2$ tests for categorical variables. Survival analyses were based on the time to a first event. Kaplan-Meier risks at 36 months were calculated. We used stratified Cox proportional hazards regression models to estimate hazard ratios (HRs) and corresponding 95% CIs to compare the effects of antithrombotic regimens in patients with and without diabetes mellitus. Significance was tested with the use of stratified log-rank testing.
tests. The assumption of the proportional hazards was verified by use of the plots of the log of the negative log of survival function against the log of time. Interaction between the effect of treatment with rivaroxaban/aspirin and diabetes mellitus status was tested in a stratified Cox model fitted to all patients. The Gail-Simon test for qualitative interactions was used to test for interaction of absolute risk reduction, with the null hypothesis that not all of the subgroup reductions

### Table 1. Baseline Characteristics of Patients With and Without Diabetes Mellitus at Baseline Randomized to Rivaroxaban Plus Aspirin or to Placebo Plus Aspirin

| Characteristic                                      | No Diabetes Mellitus (n=11356) | Diabetes Mellitus (n=6922) | P Value |
|----------------------------------------------------|-------------------------------|---------------------------|---------|
| Age, y                                             | 69.0±7.7                      | 67.0±8.2                  | <0.0001 |
| Female                                             | 2370 (20.9)                   | 1678 (24.2)               | <0.0001 |
| Body mass index, kg/m²                              | 27.7±4.3                      | 29.3±5.2                  | <0.0001 |
| Systolic blood pressure, mm Hg                     | 135±18                        | 136±17                    | <0.0001 |
| Diastolic blood pressure, mm Hg                    | 78±10                         | 77±10                     | 0.01    |
| Total cholesterol, mmol/L                          | 4.2±1.0                       | 4.2±1.1                   | <0.0001 |
| Tobacco use                                        |                               |                           |         |
| Never                                              | 3602 (31.7)                   | 2223 (32.1)               | 0.58    |
| Former                                             | 5456 (48.0)                   | 3081 (44.5)               | <0.0001 |
| Current                                            | 2298 (20.2)                   | 1618 (23.4)               | <0.0001 |
| Hypertension                                       | 8089 (71.2)                   | 5695 (82.3)               | <0.0001 |
| Previous stroke                                    | 343 (3.0)                     | 343 (5.0)                 | <0.0001 |
| Previous myocardial infarction                     | 7720 (63.6)                   | 4155 (60.0)               | <0.0001 |
| Heart failure                                      | 2328 (20.5)                   | 1614 (23.3)               | <0.0001 |
| Coronary artery disease                            | 10 491 (92.4)                 | 6083 (87.9)               | <0.0001 |
| Peripheral artery disease                          | 2792 (24.6)                   | 2204 (31.8)               | <0.0001 |
| Estimated glomerular filtration rate, mL/min       |                               |                           |         |
| <30                                                | 64 (0.6)                      | 99 (1.4)                  | <0.0001 |
| 30–<60                                             | 2357 (20.8)                   | 1648 (23.8)               | <0.0001 |
| ≥60                                                | 8932 (78.7)                   | 5174 (74.8)               | <0.0001 |
| Race                                               |                               |                           |         |
| White                                              | 7647 (67.3)                   | 3708 (53.6)               | <0.0001 |
| Black                                              | 68 (0.6)                      | 100 (1.4)                 | <0.0001 |
| Asian                                              | 1507 (13.3)                   | 1341 (19.4)               | <0.0001 |
| Other                                              | 2134 (18.8)                   | 1773 (25.6)               | <0.0001 |
| Geographic region                                  |                               |                           |         |
| North America                                      | 1616 (14.2)                   | 997 (14.4)                | 0.75    |
| South America                                      | 2274 (20.0)                   | 1834 (26.5)               | <0.0001 |
| Western Europe, Israel, Australia, or South Africa | 4037 (35.5)                   | 1673 (24.2)               | <0.0001 |
| Eastern Europe                                     | 2032 (17.9)                   | 1179 (17.0)               | 0.14    |
| Asia-Pacific                                       | 1397 (12.3)                   | 1239 (17.9)               | <0.0001 |
| Medication                                         |                               |                           |         |
| Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker | 7836 (69.0) | 5101 (73.7) | <0.0001 |
| Calcium-channel blocker                             | 2800 (24.7)                   | 2095 (30.3)               | <0.0001 |
| Diuretic                                           | 3010 (26.5)                   | 2463 (35.6)               | <0.0001 |
| β-Blocker                                          | 7917 (69.7)                   | 4866 (70.3)               | 0.41    |
| Lipid-lowering agent                                | 10 322 (90.9)                 | 6075 (87.8)               | <0.0001 |
| Nonsteroidal anti-inflammatory drug                 | 578 (5.1)                     | 426 (6.2)                 | 0.002   |
| Hypoglycemic agent                                  | 35 (0.3)                      | 5691 (82.2)               | <0.0001 |
| Nontrial proton pump inhibitor                      | 4120 (36.3)                   | 2412 (34.8)               | 0.05    |

For continuous variables, values are mean±SD; for categorical variables, n (%) is shown. P value is from the Wilcoxon 2-sample test for continuous variables and Pearson χ² test for categorical variables.
favored rivaroxaban plus aspirin. All reported \( P \) values are 2 sided. No adjustments were made for multiple subgroup or end-point comparisons; therefore, all results presented herein should be viewed as hypothesis generating. Analyses were performed with SAS software for Linux, version 9.4 (SAS Institute Inc, Cary, NC).

RESULTS

Of the 27 395 randomized patients with stable atherosclerosis in COMPASS, 10 341 had diabetes mellitus at enrollment and 17 054 did not. A total of 18 278 patients were randomized to the combination of rivaroxaban and aspirin or aspirin alone in the COMPASS trial. Of these, 6922 had diabetes mellitus at baseline and 11 356 did not have diabetes mellitus. Baseline characteristics of those with and without diabetes mellitus from the entire trial are shown in Table I in the Data Supplement, and those from the rivaroxaban plus aspirin and placebo plus aspirin arms are shown in Table 1. Those with diabetes mellitus were significantly younger and more likely female; it is not surprising that there were several other significant differences between the 2 groups. Table II in the Data Supplement shows the baseline characteristics in the rivaroxaban plus aspirin and rivaroxaban plus placebo arms in those with diabetes mellitus, and Table III in the Data Supplement provides this information for those without diabetes mellitus.

The primary efficacy end point for aspirin plus low-dose rivaroxaban versus aspirin plus rivaroxaban placebo in those with and without diabetes mellitus is shown in Figure 1. Table 2 provides several efficacy and safety comparisons. There was a consistent and similar relative risk reduction for benefit of rivaroxaban plus aspirin versus aspirin alone in patients with and without diabetes mellitus for the primary efficacy end point and the secondary end points, including mortality (Figure 2). However, because of their higher baseline risk, although the absolute risk reductions appeared larger in patients with versus without diabetes mellitus, both subgroups derived similar benefit (Kaplan-Meier event rates, 2.3% versus 1.4% for the primary end point at 3 years, Gail-Simon qualitative \( P_{interaction} < 0.0001 \); 1.9% versus 0.6% for all-cause mortality, \( P_{interaction} = 0.02 \)); the respective number needed to treat for 3 years was 44 versus 73 and 54 versus 167.

Figure 1. Cardiovascular death, myocardial infarction, or stroke.
Kaplan-Meier event curves for patients with and without diabetes mellitus randomized to aspirin plus placebo or aspirin plus low-dose rivaroxaban. The primary end point of cardiovascular death, myocardial infarction, or stroke is shown. Percentages are Kaplan-Meier risks at 3 years. ARR indicates absolute risk reduction; and HR, hazard ratio.
Table 2. Outcomes in Patients With and Without Diabetes Mellitus for Rivaroxaban Plus Aspirin Versus Placebo Plus Aspirin

| Outcome | Rivaroxaban Plus Aspirin (n=9152) | Placebo Plus Aspirin (n=9126) | Rivaroxaban Plus Aspirin vs Placebo Plus Aspirin | P Value | P Value for Interaction* |
|---------|-----------------------------------|------------------------------|-----------------------------------------------|---------|------------------------|
| **Efficacy outcomes** | | | | | |
| | First Events/Patients, n (%) | Kaplan-Meier Risk at 36 mo, % | First Events/Patients, n (%) | Kaplan-Meier Risk at 36 mo, % | Hazard Ratios (95% CIs) |
| **Cardiovascular death, stroke, or myocardial infarction** | | | | | |
| No diabetes mellitus at baseline | 200/5704 (3.5) | 5.8 | 257/5652 (4.5) | 7.2 | 0.77 (0.64–0.93) | 0.005 |
| Diabetes mellitus at baseline | 179/3448 (5.2) | 8.4 | 239/3474 (6.9) | 10.7 | 0.74 (0.61–0.90) | 0.002 |
| **Death resulting from any cause** | | | | | |
| No diabetes mellitus at baseline | 166/5704 (2.9) | 5.1 | 197/5652 (3.5) | 5.7 | 0.84 (0.68–1.03) | 0.09 |
| Diabetes mellitus at baseline | 147/3448 (4.3) | 6.8 | 181/3474 (5.2) | 8.6 | 0.81 (0.65–1.00) | 0.05 |
| **Cardiovascular death** | | | | | |
| No diabetes mellitus at baseline | 83/5704 (1.5) | 2.7 | 104/5652 (1.8) | 2.9 | 0.79 (0.59–1.06) | 0.11 |
| Diabetes mellitus at baseline | 77/3448 (2.2) | 3.5 | 99/3474 (2.8) | 4.9 | 0.77 (0.58–1.04) | 0.09 |
| **Stroke** | | | | | |
| No diabetes mellitus at baseline | 37/5704 (0.6) | 1.4 | 69/5652 (1.2) | 2.0 | 0.53 (0.36–0.79) | 0.002 |
| Diabetes mellitus at baseline | 46/3448 (1.3) | 2.2 | 73/3474 (2.1) | 3.6 | 0.63 (0.43–0.90) | 0.01 |
| **Ischemic or uncertain stroke** | | | | | |
| No diabetes mellitus at baseline | 29/5704 (0.5) | 1.2 | 62/5652 (1.1) | 1.7 | 0.46 (0.30–0.72) | 0.0005 |
| Diabetes mellitus at baseline | 39/3448 (1.1) | 1.9 | 70/3474 (2.0) | 3.5 | 0.55 (0.37–0.82) | 0.003 |
| **Myocardial infarction** | | | | | |
| No diabetes mellitus at baseline | 100/5704 (1.8) | 2.8 | 107/5652 (1.9) | 2.9 | 0.93 (0.71–1.22) | 0.59 |
| Diabetes mellitus at baseline | 78/3448 (2.3) | 3.7 | 98/3474 (2.8) | 4.0 | 0.79 (0.59–1.06) | 0.12 |
| **Major adverse limb events** | | | | | |
| No diabetes mellitus at baseline | 12/5704 (0.2) | 0.3 | 30/5652 (0.5) | 0.8 | 0.40 (0.20–0.78) | 0.005 |
| Diabetes mellitus at baseline | 22/3448 (0.6) | 1.2 | 34/3474 (1.0) | 1.6 | 0.65 (0.38–1.11) | 0.11 |
| **Total vascular amputation** | | | | | |
| No diabetes mellitus at baseline | 3/5704 (<0.1) | 0.06 | 7/5652 (0.1) | 0.2 | 0.43 (0.11–1.65) | 0.20 |
| Diabetes mellitus at baseline | 12/3448 (0.3) | 0.5 | 24/3474 (0.7) | 1.2 | 0.50 (0.25–1.00) | 0.04 |
| **Cardiovascular death, stroke, myocardial infarction, major adverse limb events, or major vascular amputation** | | | | | |
| No diabetes mellitus at baseline | 212/5704 (3.7) | 6.1 | 282/5652 (5.0) | 7.8 | 0.74 (0.62–0.89) | 0.001 |
| Diabetes mellitus at baseline | 201/3448 (5.8) | 9.4 | 272/3474 (7.8) | 12.1 | 0.73 (0.61–0.88) | 0.0007 |
| **Safety outcomes** | | | | | |
| **Major bleeding** | | | | | |
| No diabetes mellitus at baseline | 178/5704 (3.1) | 4.4 | 105/5652 (1.9) | 3.2 | 1.69 (1.33–2.15) | <0.0001 |
| Diabetes mellitus at baseline | 110/3448 (3.2) | 4.5 | 65/3474 (1.9) | 3.4 | 1.70 (1.25–2.31) | 0.0006 |
| **Intracranial major bleeding** | | | | | |
| No diabetes mellitus at baseline | 17/5704 (0.3) | 0.4 | 17/5652 (0.3) | 0.7 | 0.99 (0.51–1.95) | 0.98 |
| Diabetes mellitus at baseline | 11/3448 (0.3) | 0.4 | 7/3474 (0.2) | 0.4 | 1.57 (0.61–4.05) | 0.35 |
| **Fatal bleeding** | | | | | |
| No diabetes mellitus at baseline | 10/5704 (0.2) | 0.4 | 7/5652 (0.1) | 0.2 | 1.43 (0.55–3.77) | 0.46 |
| Diabetes mellitus at baseline | 5/3448 (0.1) | 0.2 | 3/3474 (<0.1) | 0.2 | 1.66 (0.40–6.93) | 0.48 |
| **Net clinical benefit outcomes** | | | | | |
| Cardiovascular death, stroke, myocardial infarction, fatal bleeding, or symptomatic bleeding into critical organ | | | | | |
| No diabetes mellitus at baseline | 227/5704 (4.0) | 6.6 | 276/5652 (4.9) | 7.6 | 0.81 (0.68–0.97) | 0.02 |

(Continued)
In an evaluation of the totality of ischemic events (cardiovascular death, stroke, MI, major adverse limb events, or major vascular amputation) at 3 years, those without diabetes mellitus at baseline had a significant reduction to 6.1% from 7.8% (HR, 0.74 [95% CI, 0.62–0.89]; \( P = 0.001 \)) with dual pathway antithrombotic therapy; in those with diabetes mellitus, the corresponding rates were 9.4% and 12.1% (HR, 0.73 [95% CI, 0.61–0.88]; \( P = 0.0007 \); Table 2). Although the HRs were similar, the absolute risk reductions were 1.7% and 2.7%, respectively (Gail-Simon qualitative interaction \( P < 0.0001 \); Figure 3). The respective number needed to treat for 3 years was 60 versus 38.

As in the trial overall, there was a significant increase in major bleeding with the dual pathway regimen in the subgroups with and without diabetes mellitus.
with a similar degree of risk increase. In those without diabetes mellitus, major bleeding was increased at 3 years to 4.4% from 3.2% (HR 1.69 [95% CI, 1.33–2.15]; P<0.0001). In those with diabetes mellitus, major bleeding was increased at 3 years to 4.5% from 3.4% (HR, 1.69 [95% CI, 1.33–2.15]; P=0.0006; P_interaction=0.97). There were no significant increases in intracranial or fatal bleeding. The absolute net clinical benefit for dual pathway inhibition with our prespecified definition was numerically greater (2.7% versus 1.0%) in those with versus those without diabetes mellitus, although both subgroups derived similar benefit (Gail-Simon qualitative P_interaction=0.001; Figure 4). In a nonprespecified post hoc analysis, major bleeding was combined with the primary efficacy end point, and this resulted in no significant difference between treatment arms in either those with or without diabetes mellitus (Table 2). There was no significant interaction with randomization to proton pump inhibitor versus placebo on the increased risk of major bleeding with rivaroxaban in the patients with diabetes mellitus (Table IV in the Data Supplement).

Results were similar in those with diabetes mellitus treated with medications versus those with diabetes mellitus but not receiving diabetes mellitus medications at baseline (Table 3). Consistent results were also seen in the patients with diabetes mellitus with or without a history of ischemic events (MI, unstable angina, stroke, transient ischemic attack) and with or without a history of revascularization (percutaneous coronary intervention, coronary artery bypass grafting, peripheral artery intervention, peripheral artery bypass surgery; Table 4).

**DISCUSSION**

This prespecified analysis of COMPASS shows that patients with stable atherosclerosis with concomitant diabetes mellitus have similar relative but, because of their more dismal prognosis, numerically greater absolute risk reductions in ischemic events than those without diabetes mellitus. This greater absolute efficacy occurs without any incremental increase in major bleeding complications in those with versus those without diabetes mellitus.
Thus, the net clinical benefit for irreversible outcomes appears greater in those with versus those without diabetes mellitus. This finding makes the use of dual pathway inhibition with aspirin plus low-dose rivaroxaban particularly attractive in this high-risk population.

Patients with atherosclerosis and diabetes mellitus are a very high-risk group. Despite several advances in different therapeutic areas such as lipid, blood pressure, and glycemic control, patients with diabetes mellitus continue to have high rates of recurrent ischemic events. The population of patients with diabetes mellitus studied in COMPASS represents a very broad representation of secondary prevention, including patients with coronary artery disease, peripheral artery disease, and carotid disease. Patients had prior ischemic events or stable atherosclerosis without such a history. Patients with a history of revascularization and those without prior revascularization were enrolled in COMPASS, and all these subgroups appeared to have a consistent benefit in the overall trial and in the patients with diabetes mellitus. This latter observation does distinguish these results from the multiple trials of dual antiplatelet therapy that also show significant benefit and suggest greater absolute risk reductions in those with diabetes mellitus but that have not demonstrated convincing benefit in as diverse a group of patients with atherosclerosis outside of those with prior ischemic events or prior stenting. It is worth noting, however, that ischemic event rates in patients with diabetes mellitus in COMPASS treated with aspirin plus low-dose rivaroxaban were still higher than the rate in those without diabetes mellitus treated with placebo. Thus, there is further room for residual risk reduction.

In the setting of diabetic primary prevention, aspirin has been found to be superior to placebo, even in the contemporary era, although predictably bleeding was increased. However, with careful patient selection, there are patients with diabetes mellitus without evident atherosclerosis who have a favorable net clinical benefit. Now, in the secondary prevention of patients with diabetes mellitus, it is also clear that intensifying the antithrombotic regimen beyond aspirin alone is warranted in patients who are at an acceptable risk of bleeding. Examination of the prespecified definition of net clinical benefit.
Table 3. Outcomes in Patients With Diabetes Mellitus (Untreated and Treated With Hypoglycemic Agents) and Without Diabetes Mellitus for Rivaroxaban Plus Aspirin Versus Placebo Plus Aspirin

|                                                                                                                  | Rivaroxaban Plus Aspirin (n=9152) | Placebo Plus Aspirin (n=9126) | Rivaroxaban Plus Aspirin vs Placebo Plus Aspirin |
|------------------------------------------------------------------------------------------------------------------|-----------------------------------|--------------------------------|-------------------------------------------------|
| **First Events/ Patients, n (%)**                                                                               | First Events/ Patients, n (%)     | Hazard Ratios (95% CIs)         | **P Value**                                      | **P Value for Interaction*** |
| **Kaplan-Meier Risk at 36 mo, %**                                                                                | Kaplan-Meier Risk at 36 mo, %     | **P Value**                      |                                                  |                                |
| **Efficacy outcomes**                                                                                           |                                   | **P Value**                      |                                                  |                                |
| Cardiovascular death, stroke, or myocardial infarction                                                         | 200/5704 (3.5)                    | 257/5652 (4.5)                  | 0.77 (0.64–0.93)                                | 0.005                          |
| No diabetes mellitus at baseline                                                                                 | 5.8                               | 7.2                             |                                                  |                                |
| Diabetes mellitus and treated                                                                                    | 146/2820 (5.2)                    | 197/2871 (6.9)                  | 0.73 (0.59–0.91)                                | 0.004                          |
| Diabetes mellitus and not treated                                                                                | 33/628 (5.3)                      | 42/603 (7.0)                    | 0.78 (0.50–1.24)                                | 0.29                           |
| Death resulting from any cause                                                                                  | 166/5704 (2.9)                    | 197/5652 (3.5)                  | 0.84 (0.68–1.03)                                | 0.09                           |
| No diabetes mellitus at baseline                                                                                 | 5.1                               | 5.7                             |                                                  |                                |
| Diabetes mellitus and treated                                                                                    | 119/2820 (4.2)                    | 141/2871 (4.9)                  | 0.84 (0.66–1.07)                                | 0.17                           |
| Diabetes mellitus and not treated                                                                                | 28/628 (4.5)                      | 40/603 (6.6)                    | 0.69 (0.43–1.13)                                | 0.14                           |
| **Cardiovascular death**                                                                                         | 0.94                              | 0.75                            |                                                  |                                |
| No diabetes mellitus at baseline                                                                                 | 83/5704 (1.5)                     | 104/5652 (1.8)                  | 0.79 (0.59–1.06)                                | 0.11                           |
| Diabetes mellitus and treated                                                                                    | 64/2820 (2.3)                     | 77/2871 (2.7)                   | 0.83 (0.59–1.15)                                | 0.26                           |
| Diabetes mellitus and not treated                                                                                | 13/628 (2.1)                      | 22/603 (3.6)                    | 0.60 (0.30–1.19)                                | 0.14                           |
| **Stroke**                                                                                                       | 0.66                              | 0.59                            |                                                  |                                |
| No diabetes mellitus at baseline                                                                                 | 37/5704 (0.6)                     | 69/5652 (1.2)                   | 0.53 (0.36–0.79)                                | 0.002                          |
| Diabetes mellitus and treated                                                                                    | 41/2820 (1.5)                     | 62/2871 (2.2)                   | 0.66 (0.44–0.98)                                | 0.04                           |
| Diabetes mellitus and not treated                                                                                | 5/628 (0.8)                       | 11/603 (1.8)                    | 0.44 (0.15–1.26)                                | 0.12                           |
| **Ischemic or uncertain stroke**                                                                                | 0.59                              | 0.41                            |                                                  |                                |
| No diabetes mellitus at baseline                                                                                 | 29/5704 (0.5)                     | 62/5652 (1.1)                   | 0.46 (0.30–0.72)                                | 0.0005                         |
| Diabetes mellitus and treated                                                                                    | 35/2820 (1.2)                     | 59/2871 (2.1)                   | 0.59 (0.39–0.90)                                | 0.01                           |
| Diabetes mellitus and not treated                                                                                | 4/628 (0.6)                       | 11/603 (1.8)                    | 0.35 (0.11–1.09)                                | 0.06                           |
| **Myocardial infarction**                                                                                        | 0.41                              | 0.49                            |                                                  |                                |
| No diabetes mellitus at baseline                                                                                 | 100/5704 (1.8)                    | 107/5652 (1.9)                  | 0.93 (0.71–1.22)                                | 0.59                           |
| Diabetes mellitus and treated                                                                                    | 60/2820 (2.1)                     | 82/2871 (2.9)                   | 0.73 (0.52–1.01)                                | 0.06                           |
| Diabetes mellitus and not treated                                                                                | 18/628 (2.9)                      | 16/603 (2.7)                    | 1.13 (0.57–2.21)                                | 0.73                           |
| **Major adverse limb events**                                                                                    | 0.49                              | 0.77                            |                                                  |                                |
| No diabetes mellitus at baseline                                                                                 | 12/5704 (0.2)                     | 30/5652 (0.5)                   | 0.80 (0.20–0.78)                                | 0.005                          |
| Diabetes mellitus and treated                                                                                    | 20/2820 (0.7)                     | 32/2871 (1.1)                   | 0.63 (0.36–1.10)                                | 0.10                           |
| Diabetes mellitus and not treated                                                                                | 2/628 (0.3)                       | 2/603 (0.3)                     | 0.96 (0.14–6.85)                                | 0.97                           |
| **Total vascular amputation**                                                                                    | 0.77                              | 0.97                            |                                                  |                                |
| No diabetes mellitus at baseline                                                                                 | 3/5704 (<0.1)                     | 7/5652 (0.1)                    | 0.43 (0.11–1.65)                                | 0.20                           |
| Diabetes mellitus and treated                                                                                    | 10/2820 (0.4)                     | 22/2871 (0.8)                   | 0.46 (0.22–0.97)                                | 0.04                           |
| Diabetes mellitus and not treated                                                                                | 2/628 (0.3)                       | 2/603 (0.3)                     | 1.04 (0.15–7.36)                                | 0.97                           |
| **Cardiovascular death, stroke, myocardial infarction, major adverse limb events, or major vascular amputation** | 0.97                              | 0.90                            |                                                  |                                |
| No diabetes mellitus at baseline                                                                                 | 212/5704 (3.7)                    | 282/5652 (5.0)                  | 0.74 (0.62–0.89)                                | 0.001                          |
| Diabetes mellitus and treated                                                                                    | 166/2820 (5.9)                    | 227/2871 (7.9)                  | 0.72 (0.59–0.88)                                | 0.001                          |
| Diabetes mellitus and not treated                                                                                | 35/628 (5.6)                      | 45/603 (7.5)                    | 0.77 (0.50–1.20)                                | 0.25                           |
| **Safety outcomes**                                                                                               | 0.90                              | 0.90                            |                                                  |                                |
| Major bleeding                                                                                                   | 178/5704 (3.1)                    | 105/5652 (1.9)                  | 1.69 (1.33–2.15)                                | <0.0001                        |
| Diabetes mellitus and treated                                                                                    | 95/2820 (3.4)                     | 58/2871 (2.0)                   | 1.66 (1.20–2.30)                                | 0.002                          |

(Continued)
benefit in COMPASS, consisting of irreversible harms, demonstrated significant benefit for dual pathway inhibition, whereas a post hoc definition of net clinical benefit incorporating all major bleeding did not demonstrate significant benefit. However, although major bleeding is important, it is not appropriate to weight it equivalently to MI, ischemic stroke, amputations, or certainly all-cause mortality.42

Limitations of this analysis include that it is a subgroup not specifically powered for efficacy or safety assessments, although the analysis was prespecified. The early stopping of the trial further limits the power of subgroup analysis, although the independent data and safety monitoring board felt that the trial needed to be stopped as a result of overwhelming efficacy, including a reduction in all-cause mortality that echoed a prior trial with this double antithrombotic regimen.43,44 Nevertheless, sufficient statistical power was present to demonstrate a significant reduction in the primary end point in the overall trial and in those with and without diabetes mellitus, increasing confidence in the subgroup analyses presented herein. Another limitation is that diabetes mellitus was defined only by case history, and duration of diabetes mellitus was not captured in the case report form. Some prior studies of antiplatelet agents have shown a gradient of benefit among those treated with insulin versus oral medications versus diet only; however, insulin treatment was not captured.45,46

CONCLUSIONS

Aspirin plus low-dose rivaroxaban reduces major cardiovascular events versus aspirin alone in patients with stable atherosclerosis, regardless of the presence or absence of diabetes mellitus, although the absolute risk reductions are numerically larger in those with diabetes mellitus.
Table 4. Effect of Antithrombotic Therapies in Subgroups of Patients With Diabetes Mellitus

| Outcome                                                                 | History of prior ischemic events at baseline | Rivaroxaban Plus Aspirin (n=3448) | Placebo Plus Aspirin (n=3474) | Rivaroxaban Plus Aspirin vs Placebo Plus Aspirin |
|------------------------------------------------------------------------|----------------------------------------------|-----------------------------------|------------------------------|-----------------------------------------------|
|                                                                      | First Events/ Patients, n (%) | Kaplan-Meier Risk at 36 mo, % | First Events/ Patients, n (%) | Kaplan-Meier Risk at 36 mo, % | Hazard Ratios (95% CIs) | P Value | P Value for Interaction* |
| **Cardiovascular death, stroke, or myocardial infarction**             |                               |                                  |                               |                               |                               |         |                           |
| History of prior ischemic events at baseline                           | No                             | 42937 (4.5)                      | 8.8                           | 57981 (5.8)                      | 10.1                          | 0.76 (0.51–1.14) | 0.18          |
|                                                                      | Yes                            | 1372511 (5.5)                    | 8.3                           | 1822493 (7.3)                    | 11.0                          | 0.73 (0.59–0.91) | 0.006         |
| History of prior revascularization at baseline                         | No                             | 58978 (5.9)                      | 10.0                          | 851068 (8.0)                     | 12.8                          | 0.73 (0.52–1.02) | 0.06          |
|                                                                      | Yes                            | 1212470 (4.9)                    | 7.9                           | 1542406 (6.4)                    | 9.9                           | 0.75 (0.59–0.95) | 0.02          |
| History of prior ischemic events or revascularization at baseline      | No                             | 18416 (4.3)                      | 11.0                          | 26435 (6.0)                      | 12.3                          | 0.71 (0.39–1.30) | 0.27          |
|                                                                      | Yes                            | 1613032 (5.3)                    | 8.3                           | 2133039 (7.0)                    | 10.6                          | 0.74 (0.61–0.91) | 0.004         |
| **Major bleeding**                                                     |                               |                                  |                               |                               |                               |         |                           |
| History of prior ischemic events at baseline                           | No                             | 31937 (3.3)                      | 4.1                           | 17981 (1.7)                      | 3.4                           | 1.92 (1.06–3.47) | 0.03          |
|                                                                      | Yes                            | 792511 (3.1)                     | 4.6                           | 482493 (1.9)                     | 3.5                           | 1.63 (1.14–2.33) | 0.007         |
| History of prior revascularization at baseline                         | No                             | 25978 (2.6)                      | 3.7                           | 201068 (1.9)                     | 3.3                           | 1.34 (0.74–2.41) | 0.33          |
|                                                                      | Yes                            | 852470 (3.4)                     | 4.7                           | 452406 (1.9)                     | 3.4                           | 1.84 (1.28–2.64) | 0.001         |
| History of prior ischemic events or revascularization at baseline      | No                             | 7416 (1.7)                       | 2.2                           | 7435 (1.6)                       | 3.9                           | 1.04 (0.36–2.96) | 0.94          |
|                                                                      | Yes                            | 1033032 (3.4)                    | 4.7                           | 583039 (1.9)                     | 3.4                           | 1.78 (1.29–2.46) | 0.0004        |
| **Cardiovascular death, stroke, myocardial infarction, fatal bleeding, or symptomatic bleeding into critical organ** |                               |                                  |                               |                               |                               |         |                           |
| History of prior ischemic events at baseline                           | No                             | 52937 (5.5)                      | 9.9                           | 64981 (6.5)                      | 10.9                          | 0.85 (0.59–1.22) | 0.37          |
|                                                                      | Yes                            | 1522511 (6.1)                    | 8.8                           | 1942493 (7.8)                    | 12.1                          | 0.76 (0.62–0.95) | 0.01          |
| History of prior revascularization at baseline                         | No                             | 66978 (6.7)                      | 11.0                          | 901068 (8.4)                     | 13.5                          | 0.79 (0.57–1.08) | 0.14          |
|                                                                      | Yes                            | 1382470 (5.6)                    | 8.5                           | 1682406 (7.0)                    | 11.1                          | 0.79 (0.63–0.99) | 0.04          |
| History of prior ischemic events or revascularization at baseline      | No                             | 21416 (5.0)                      | 11.9                          | 29435 (6.7)                      | 13.0                          | 0.75 (0.43–1.31) | 0.31          |
|                                                                      | Yes                            | 1833032 (6.0)                    | 9.0                           | 2293039 (7.5)                    | 11.7                          | 0.79 (0.65–0.96) | 0.02          |
| **Cardiovascular death, stroke, myocardial infarction, or major bleeding** |                               |                                  |                               |                               |                               |         |                           |
| History of prior ischemic events at baseline                           | No                             | 69937 (7.4)                      | 12.4                          | 72981 (7.3)                      | 12.7                          | 1.01 (0.72–1.40) | 0.97          |
|                                                                      | Yes                            | 2002511 (8.0)                    | 11.5                          | 2192493 (8.8)                    | 13.2                          | 0.90 (0.74–1.09) | 0.27          |
| History of prior revascularization at baseline                         | No                             | 79978 (8.1)                      | 13.0                          | 1021068 (9.6)                    | 15.7                          | 0.83 (0.62–1.11) | 0.21          |
|                                                                      | Yes                            | 1902470 (7.7)                    | 11.3                          | 1892406 (7.9)                    | 12.1                          | 0.98 (0.80–1.20) | 0.82          |
| History of prior ischemic events or revascularization at baseline      | No                             | 24416 (5.8)                      | 13.0                          | 33435 (7.6)                      | 16.1                          | 0.75 (0.44–1.27) | 0.28          |
|                                                                      | Yes                            | 2453032 (8.1)                    | 11.8                          | 2583039 (8.5)                    | 12.8                          | 0.95 (0.80–1.13) | 0.55          |

Percent is the proportion of patients with an outcome. Hazard ratios (95% CIs) are from the stratified Cox proportional hazards regression models fit in the respective subgroup. P values are from the stratified log-rank test.

*Test of interaction of relative risk reduction (Cox regression).
Bhatt et al

COMPASS Diabetes Mellitus

University and Hamilton Health Sciences, Ontario, Canada (J.W.E., S.J.C., S.S.A., J.B., O.S., S.Y.). Université de Paris and Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, France (P.G.S.). Division of Cardiac Surgery, St Michael’s Hospital, University of Toronto, Ontario, Canada (S.V.). University of Washington Medical Centre, Seattle (K.R.H.B., J.P.). School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada (J.B.). State University of New York, Downstate School of Public Health, Brooklyn (M.S.). ANMCO Research Center, Valencia, Italy (A.P.M.). Third Faculty of Medicine, Charles University, and University Hospital Královské Vinohrady, Prague, Czech Republic (P.W.). Hospital Alemao Oswaldo Cruz, São Paulo, Brazil (A.A.). Estudios Clinicos Latinoamérica, Rosario, Argentina (R.D.). Instituto Cardiovascular de Rosario, Argentina (R.D.). Lady Davis Carmel Medical Centre and the Technion-Israel Institute of Technology, Haifa (B.S.L.). Bayer US LLC, Whippany, NJ (S.D.B.). Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (K.A.F.).

Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden (L.R.).

Sources of Funding

The COMPASS study was funded by Bayer AG.

Disclosures

Dr Bhatt discloses the following relationships: Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, PLX Pharma, and Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by Abbott, now Abbott); Mayo Clinic (including for the ExCED trial, funded by Edwards); Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE-AIT trial, funded by Daichi Sankyo), and Population Health Research Institute; honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; vice chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-IV executive committee funded by CSL Behring), and WebMD (Continuing Medical Education steering committees); other: MJH Associates Inc (for the COMPASS Operations Committee, Publications Committee, Steering Committee, and Brazil national coleader, funded by Bayer), lecture fees from Bayer and Boehringer-Ingelheim, and research funding from Sanofi-Aventis. Dr Diaz has received research grants from Sanofi, Eli Lilly, Amgen, Population Health Research Institute, Duke Clinical Research Institute, Montreal Health Research Coordinating Center, Lepeit Sà, Dalcor, Cirius Therapeutics, and Heart Initiative and speaker fees from Sanofi, AstraZeneca, Eli Lilly, and Amgen. Dr Lewis reports research funding from Bayer Healthcare, MSD, AstraZeneca, Pfizer, and Kowa Pharmaceuticals, as well as consultant fees and honoraria from MSD and Pfizer. Dr Berkowitz is employed as a clinical research physician by Bayer US, LLC. Dr Fox received grants from Bayer/Lanssen and AstraZeneca and consulting and honoraria from Bayer/Lanssen, Sanofi/Regeneron, and Verseau. Dr Ryden reports research grants from the Swedish Heart-Lung Foundation, The Familien Erling-Perssons Foundation, private foundations, Amgen, Bayer AG, Boehringer Ingelheim, MSD, and Novo Nordisk, as well as personal fees (consulting) from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk, and Sanofi. Dr Yusuf has received grants and honoraria from Bayer, Bi, Astra, BMS, and Cadila. The other authors report no conflicts.

APPENDIX

Steering Committee: S. Yusuf, K.A.A. Fox, S. Connolly, J.W. Eikelboom, J. Bosch, V. Abiyans, M. Alings, S. Anand, A. Avezum, D.L. Bhatt, K. Branch, P. Cammerford, N. Cook-Brungs, G. Dagenais, A. Dans, R. Diaz, G. Efti, C. Felix, T. Guzik, R. Hart, M. Hori, A. Kakkar, K. Keltai, M. Keltai, J. Kim, A. Lamy, F. Lanaca, B. Lewis, Y. Liang, L. Liu, E. Lonn, P. Lopez-Jaramillo, A. Majo, K. Metzarianne, P. Moayyedi, M. O’Donnell, A. Parkhomenko, L. Pegas, N. Pogosova, J. Probstfield, L. Ryden, M. Sharma, P. G. Steg, S. Stoek, A. Tonkin, C. Torg-Pedersen, J. Varigos, P. Verhamme, D. Vinereau, P. Widsinsky, K. Yusoff, and J. Zhu.

REFERENCES

1. Bhatt DL, Steg PG, Ohmann EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liu CS, Richard AJ, Röther J, et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189. doi: 10.1001/jama.295.2.180
2. Steg PG, Bhatt DL, Wilson PW, A. D. G. Rost, S. Ohman, E. Röther, J. Liu, S. C. Hirsch, A. Tak, Y. Ikeda, et al; REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–1206. doi: 10.1001/jama.297.11.1197
3. Bhatt DL, Eagle KA, Ohmann EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, A. D. G. Rost, S. Ohman, et al; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350–1357. doi: 10.1001/jama.2010.1322
4. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohmann EM, Goto S, Kuder J, Im K, Wilson PW, B. D. M. D. R. E. T., B. H. A. N. S. O. N. O. S. et al; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350–1357. doi: 10.1001/jama.2010.1322
5. Alberts MJ, Bhatt DL, Mas JL, Ohmann EM, Hirsch AT, Röther J, Salate G, Goto S, Smith SC Jr, Liu CS, et al; RÉDUCTION d’Atherothrombose pour Continuer la Santé et la Réduction de la Mortalité par les Agents Antithrombotiques (REDUCE-IT) Study Investigators. Three-year follow-up and event rates in the international REDUCE-IT Study for Continuation Heart (REACH) Registry. Circulation. 2015;132:923–931. doi: 10.1161/CIRCULATIONAHA.114.014796
6. Alberts MJ, Bhatt DL, Mas JL, Ohmann EM, Hirsch AT, Röther J, Salate G, Goto S, Smith SC Jr, Liu CS, et al; RÉDUCTION d’Atherothrombose pour Continuer la Santé et la Réduction de la Mortalité par les Agents Antithrombotiques (REDUCE-IT) Study Investigators. Three-year follow-up and event rates in the international REDUCE-IT Study for Continuation Heart (REACH) Registry. Eur Heart J. 2009;30:2318–2326. doi: 10.1038/eurheartj.2009.355

June 9, 2020
Circulation. 2020;141:1841–1854. DOI: 10.1161/CIRCULATIONAHA.120.046448
Verma S, Bhatt DL. More CREDENCE for SGLT2 Inhibition. Circulation. 2019;140:1448–1450. doi: 10.1161/CIRCULATIONAHA.119.041181

Verma S, Poulet NR, Bhatt DL, Bain SC, Buse JB, Nauck MA, Prattley RE, Zinman B, Ørsted DD, et al. Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation. 2018;138:2884–2894. doi: 10.1161/CIRCULATIONAHA.118.034516

Verma S, Mazer CD, Bhatt DL. The perils of polypharmacy in type 2 diabetes. Lancet Diabetes Endocrinol. 2018;6:914–916. doi: 10.1016/S2213-8587(18)30311-3

Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulet NR, Prattley RE, Zinman B, et al. LEADER Publication Committee. More CREDENCE for SGLT2 Inhibition: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:941–950. doi: 10.1016/S2213-8587(19)30158-5

Verma S, Bhatt DL. More CREDENCE for SGLT2 Inhibition. Circulation. 2019;140:1448–1450. doi: 10.1161/CIRCULATIONAHA.119.041181

Verma S, Poulet NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Prattley RE, Zinman B, Ørsted DD, et al. Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation. 2018;138:2884–2894. doi: 10.1161/CIRCULATIONAHA.118.034516

Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulet NR, Prattley RE, Zinman B, et al. LEADER Publication Committee. More CREDENCE for SGLT2 Inhibition: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:941–950. doi: 10.1016/S2213-8587(19)30158-5

Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulet NR, Prattley RE, Zinman B, et al. LEADER Publication Committee. More CREDENCE for SGLT2 Inhibition: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:941–950. doi: 10.1016/S2213-8587(19)30158-5

Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulet NR, Prattley RE, Zinman B, et al. LEADER Publication Committee. More CREDENCE for SGLT2 Inhibition: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:941–950. doi: 10.1016/S2213-8587(19)30158-5

Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulet NR, Prattley RE, Zinman B, et al. LEADER Publication Committee. More CREDENCE for SGLT2 Inhibition: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:941–950. doi: 10.1016/S2213-8587(19)30158-5

Bhatt DL, Fox KK, Harrington RA, Leiter LA, Mehta SR, Simon T, Anderson M, Himmelmann A, Riddershæde W, Held C, et al. THEMIS Steering Committee. Rationale, design and baseline characteristics of the effect of Ticagrelor on Health Outcomes in Diabetes Mellitus: Patients Intervention study. Clin Cardiol. 2019;42:498–505. doi: 10.1002/cc.23164

Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Anderson M, Himmelmann A, Riddershæde W, et al. THEMIS Steering Committee and Investigators. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381:1309–1320. doi: 10.1056/NEJMoa1908077

Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Anderson M, Himmelmann A, Riddershæde W, et al. THEMIS Steering Committee and Investigators. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a place 3, placebo-controlled, randomised trial. Lancet. 2019;394:1169–1180. doi: 10.1016/S0140-6736(19)31887-2

Bosch J, Eikelboom JW, Connolly SJ, Brosens NC, Lianus V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M, et al. Rationale, design and baseline characteristics of patients in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017;33:1027–1035. doi: 10.1016/j.cjca.2017.06.001

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–1330. doi: 10.1056/NEJMoa1709118

Connolly SJ, Eikelboom JW, Pisters MA, Kodama S, Dagenais GR, Lonn EM, Alings M, et al. Complications in patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37:390–399. doi: 10.1093/eurheartj/ehv443

Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Anderson M, Himmelmann A, Riddershæde W, et al. THEMIS Steering Committee. Rationale, design and baseline characteristics of the effect of Ticagrelor on Health Outcomes in Diabetes Mellitus: Patients Intervention study. Clin Cardiol. 2019;42:498–505. doi: 10.1002/cc.23164

Bhatt DL, Fox KK, Harrington RA, Leiter LA, Mehta SR, Simon T, Anderson M, Himmelmann A, Riddershæde W, et al. THEMIS Steering Committee and Investigators. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381:1309–1320. doi: 10.1056/NEJMoa1908077

Bosch J, Eikelboom JW, Connolly SJ, Brosens NC, Lianus V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M, et al. Rationale, design and baseline characteristics of patients in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017;33:1027–1035. doi: 10.1016/j.cjca.2017.06.001

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–1330. doi: 10.1056/NEJMoa1709118

Connolly SJ, Eikelboom JW, Pisters MA, Kodama S, Dagenais GR, Lonn EM, Alings M, et al. Complications in patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37:390–399. doi: 10.1093/eurheartj/ehv443
risks among COMPASS-eligible patients. J Am Coll Cardiol. 2019;73:3281–3291. doi: 10.1016/j.jacc.2019.04.046
37. Fox KAA, Eikelboom JW, Anand SS, Bhatt DL, Bosch J, Connolly SJ, Harrington RA, Steg PG, Yusuf S. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Eur Heart J. 2019;40:1466–1471. doi: 10.1093/eurheartj/ehy347
38. Boden WE, Bhatt DL. Will COMPASS point to a new direction in thrombotic risk reduction in patients with stable cardiovascular disease? Circulation. 2018;138:858–860. doi: 10.1161/CIRCULATIONAHA.118.035405
39. Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529–1539.
40. Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JGF, Blumenthal RS, McEvoy JW. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019;393:2155–2167. doi: 10.1016/S0140-6736(19)30541-0
41. Abdelaziz HK, Saad M, Pothineni NVK, Megaly M, Potluri R, Saleh M, Kon DLC, Roberts DH, Bhatt DL, Aronow HD, et al. Aspirin for primary prevention of cardiovascular events. J Am Coll Cardiol. 2019;73:2915–2929. doi: 10.1016/j.jacc.2019.03.001
42. Steg PG, Bhatt DL. Is there really a benefit to net clinical benefit in testing antithrombotics? Circulation. 2018;137:1429–1431. doi: 10.1161/CIRCULATIONAHA.117.033442
43. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19. doi: 10.1056/NEJMoa1112277
44. Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW, Bhatt DL, Goto S, Cohen M, Mohanavelu S, et al; ATLAS-ACS 2 TIMI 51 Investigators. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol. 2013;62:286–290. doi: 10.1016/j.jacc.2013.03.041
45. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90:625–628. doi: 10.1016/s0002-9149(02)02567-5
46. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922–928. doi: 10.1016/s0735-1097(99)00650-6